天弘恒生沪深港创新药精选50ETF(517380)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
80,496,039.51 |
-29,881,927.51 |
-79,544,608.54 |
-44,417,939.12 |
| 利息合计 |
20,566.57 |
41,705.65 |
20,110.67 |
48,883.14 |
| 其中：存款利息收入 |
20,566.57 |
41,705.65 |
20,110.67 |
48,883.14 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
20,610,897.91 |
-64,921,887.87 |
-60,219,454.59 |
-27,978,028.03 |
| 其中：股票投资收益 |
18,088,989.08 |
-68,525,236.63 |
-62,237,282.21 |
-30,684,868.64 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
30,029.70 |
5,141.97 |
1.79 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
2,521,908.83 |
3,573,319.06 |
2,012,685.65 |
2,706,838.82 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
59,456,441.90 |
34,798,511.50 |
-19,463,390.77 |
-17,030,864.48 |
| 其他收入 |
408,133.13 |
199,743.21 |
118,126.15 |
542,070.25 |
| 费用 |
1,139,007.90 |
1,784,474.23 |
912,700.87 |
1,881,387.71 |
| 管理人报酬 |
809,212.25 |
1,207,388.69 |
613,135.97 |
1,270,291.64 |
| 基金托管费 |
161,842.46 |
241,477.75 |
122,627.21 |
254,058.36 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
167,953.19 |
335,607.74 |
176,937.69 |
357,037.71 |
| 利润总额 |
79,357,031.61 |
-31,666,401.74 |
-80,457,309.41 |
-46,299,326.83 |
微信公众号
证券之星APP
基本资料
